



## **Five Prime Therapeutics, Inc. to Present at Upcoming Investor Conferences**

San Francisco, CA - March 2, 2010 – Five Prime Therapeutics, Inc. announced today that Julia P. Gregory, president and chief executive officer, will present an overview of the company, discuss the progress of FivePrime's lead clinical program, FP-1039, for oncology, its preclinical pipeline and recent announcement of a milestone achievement under the Centocor Research & Development, Inc. collaboration.

### **Cowen and Company 30<sup>th</sup> Annual Healthcare Conference**

Ms. Gregory will present on Monday, March 8, 1:30 p.m. Eastern Time with Dr. W. Michael Kavanaugh, senior vice president, Research & Development. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

### **Future Leaders in the Biotech Industry**

Ms. Gregory will present on Thursday, April 8, 10:00 a.m. Eastern Time with Dr. Brian Wong, vice president, Immunology and Discovery Research. The conference will be held at the Millennium Broadway Hotel & Conference Center, New York, New York.

### **About FP-1039**

FP-1039 is a first-in-class biologic targeting the FGF/FGFR pathway in cancer. FP-1039 is a soluble fusion protein (ligand trap) designed to neutralize the activity of multiple FGFs and FGF receptors. Tumors of the breast, prostate, lung, ovary, colon, pancreas and other organs have been reported to have a strong dependence upon the FGF/FGFR pathway for survival and growth. Clinically, activation of this pathway has been correlated with both decreased survival and time to metastasis in several major cancers and escape from anti-VEGF therapy in patients. A Phase 1 study in advanced solid tumor cancers is underway to test safety and tolerability. Preliminary clinical data from this study were presented at the AACR-NCI-EORTC Molecular Targets and Novel Therapeutics Conference in November 2009.

### **About Five Prime Therapeutics, Inc.**

Five Prime Therapeutics, Inc. is a clinical-stage, privately-held company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently in Phase I with FP-1039 for solid tumors. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has built a unique suite of technologies to mine selectively the entire extracellular human proteome - the complete collection of secreted proteins and receptors - for medically relevant therapeutic protein drugs. FivePrime is collaborating with Pfizer, Inc. in the fields of oncology and diabetes. For more information, visit [www.fiveprime.com](http://www.fiveprime.com).

Five Prime Therapeutics, Inc.  
Jennifer Pratt Mead, 415-365-5663  
[jennifer.pratt@fiveprime.com](mailto:jennifer.pratt@fiveprime.com)

###